Barrett's Esophagus; Case Report

Yıl 2022, Cilt: 9 Sayı: 3, 116 - 121, 31.12.2022

Gülden Yıldız , Hatice Beşeren , Tülay Allahverdi

Öz

Barrett's esophagus is the transformation of the normal squamous epithelium in the distal esophagus into columnar epithelium with intestinal metaplasia. Barrett's esophagus generally develops as a result of chronic mucosal irritation due to gastroesophageal reflux. Although Barrett's esophagus is usually seen over the age of 50, it can also be seen at younger ages. In our case, it was seen in a 34-year-old male patient. The patient applied to the general surgery outpatient clinic with complaints of swelling in the stomach, pain and watering in the mouth. When endoscopy is performed; the cervical and thoracic esophageal mucosa appeared normal, and the Z line was 40 cm distally. The esophageal mucosa had a hyperemic appearance. Multiple biopsies were taken from these areas. In histopathological evaluation, special columnar epithelium, mucin-filled cytoplasm, goblet cells (intestinal metaplasia) were observed. Goblet cells were positively stained by PAS/Alcian Blue and Mucincarmine histochemical staining.

Anahtar Kelimeler

Barrett, gastroesophageal reflux, intestinal metaplasia

Destekleyen Kurum

None

Proje Numarası

There is no project support.

Barrett Özofagus; Olgu Sunumu

Öz

Anahtar Kelimeler

Barrett özofagus

Proje Numarası

There is no project support.

Kaynakça

• 1. De Palma GD. Management strategies of Barrett esophagus, World J Gastroenterol 2012; 18:6216-25.
• 2. Schouten LJ, Steevens J, Huysentruyt CJ, et al. Total cancer incidence and overall mortality are not increased among patients with Barret’s esophagus. Clin Gastroenterol Hepatol 2011;9:754-61.
• 3. Spechler SJ. Barret’ esophagus: Clinical issues Barrett's esophagus: Clinical issues. Gastrointest Endosc Clin N Am 2011;21:1-7.
• 4. Bhardwaj A, McGarrity TJ, Stairs DB, Mani H. Barrett's esophagus: Emerging knowledge and management strategies. Patholog Res Int 2012; 2012: 814146.
• 5. Vahabzadeh B, Seetharam AB, Cook MB, et al. Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc 2012;75:236-41.
• 6. Leggett CL, Nelsen EM, Tian J, et al. Metabolic syndrome as a risk factor for barrett esophagus: a population-based case-control study. Mayo Clin Proc 2013;88:157-65.
• 7. El-Serag HB, Hashmi A, Garcia J, et al. Visceral Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2013 Feb 13 (Epub).
• 8. Thompson OM, Beresford SA, et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010;18:2204-11.
• 9. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013 Mar 1. pii: S1542- 3565(13)00274-7.
• 10. Tytgat GN. Recent developments in gastro-esophageal reflux disease and Barrett's esophagus: J Dig Dis 2012;13:291-5.
• 11. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011;141:1179-86.
• 12. Wani S. Management of low-grade dysplasia in Barret’s esophagus. Curr Opin Gastroenterol 2012;28:370-6.
• 13. Moyes LH, Going JJ. Still waiting for predictive biomarkers in Barrett's oesophagus. J Clin Pathol 2011;64:742-50.
• 14. Verbeek RE, van Oijen MG, ten Kate FJ, et al. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study. Am J Gastroenterol 2012;107: 534-42.
• 15. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011;141:460-8.
• 16. Zhang ZF, Kurtz RC, Sun M, Karpeh M Jr, Yu GP, Gargon N, et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev 1996;5:761-8.
• 17. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1055-62.
• 18. Sartori S, Nielsen I, Indelli M, Trevisani L, Pazzi P, Grandi E. Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): an iatrogenic injury? Ann Intern Med 1991;114:210-1.
• 19. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, et al. Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323-8.
• 20. Fitzgerald RC. Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 2006;55:1810-20.
• 21. Schier S, Wright NA. Stem cell relationships and the origin of gastrointestinal cancer. Oncology 2005;69 Suppl 1:9-13.
• 22. Yu WY, Slack JM, Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol 2005;284:157-70.
• 23. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci 2002;115:1783-9.